Aliases & Classifications for Spondylarthropathy

MalaCards integrated aliases for Spondylarthropathy:

Name: Spondylarthropathy 20
Spondylarthropathies 54 6 70

Classifications:



External Ids:

UMLS 70 C0949691

Summaries for Spondylarthropathy

MalaCards based summary : Spondylarthropathy, also known as spondylarthropathies, is related to spondylitis and spondyloarthropathy 1, and has symptoms including sciatica An important gene associated with Spondylarthropathy is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Allograft rejection and Measles. The drugs Etanercept and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells.

Wikipedia : 73 Spondyloarthropathy or spondyloarthrosis refers to any joint disease of the vertebral column. As such,... more...

Related Diseases for Spondylarthropathy

Diseases related to Spondylarthropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 spondylitis 30.9 TNF HLA-B
2 spondyloarthropathy 1 30.5 TNF TLR4 HLA-B
3 spondyloarthropathy 30.3 TNF ITGAL HLA-B
4 reactive arthritis 30.1 TNF TLR4 HLA-B
5 urethritis 30.1 TNF TLR4
6 ileitis 30.1 TNF TLR4
7 chlamydia 30.0 TNF TLR4
8 enterocolitis 30.0 TNF TLR4
9 proteasome-associated autoinflammatory syndrome 1 29.8 TNF TLR4
10 iritis 29.8 TNF HLA-B
11 pyelonephritis 29.8 TNF TLR4
12 vitiligo-associated multiple autoimmune disease susceptibility 1 29.7 TNF HLA-B
13 pustulosis palmaris et plantaris 29.6 TNF ITGAL
14 acquired immunodeficiency syndrome 29.5 TNF HLA-B CD163
15 conjunctivitis 29.4 TNF TLR4 HLA-B
16 iridocyclitis 29.4 TNF TLR4 HLA-B
17 meningitis 29.3 TNF TLR4 HLA-B
18 arthritis 29.0 TNF TLR4 ITGAL HLA-B
19 immune deficiency disease 29.0 TNF ITGAL HLA-B
20 inflammatory bowel disease 28.8 TNF TLR4 ITGAL HLA-B CD163
21 psoriasis 28.7 TNF ITGAL HLA-B
22 rheumatoid arthritis 28.7 TNF TLR4 ITGAL HLA-B
23 enthesitis-related juvenile idiopathic arthritis 11.0
24 inflammatory spondylopathy 10.5
25 uveitis 10.3
26 enthesopathy 10.3
27 plica syndrome 10.2
28 synovitis 10.2
29 arthropathy 10.2
30 psoriatic arthritis 10.2
31 amyloidosis 10.2
32 bone inflammation disease 10.2
33 crohn's disease 10.2
34 drug reaction with eosinophilia and systemic symptoms 10.1 TNF HLA-B
35 necrobiosis lipoidica 10.1 TNF CD163
36 nontuberculous mycobacterial lung disease 10.1 TNF HLA-B
37 hypopyon 10.1 TNF HLA-B
38 granulomatous dermatitis 10.1 TNF CD163
39 macrophage activation syndrome 10.1 TNF CD163
40 cytomegalovirus retinitis 10.1 TNF HLA-B
41 histoplasmosis 10.1 TNF HLA-B
42 intermediate uveitis 10.1 TNF HLA-B
43 trachoma 10.1 TNF HLA-B
44 autoimmune gastritis 10.1 TNF HLA-B
45 pulpitis 10.1 TNF CD163
46 panuveitis 10.1 TNF HLA-B
47 lambert-eaton myasthenic syndrome 10.1 TNF HLA-B
48 herpes zoster 10.1 TNF HLA-B
49 graft-versus-host disease 10.1 TNF HLA-B
50 pouchitis 10.1 TNF TLR4

Graphical network of the top 20 diseases related to Spondylarthropathy:



Diseases related to Spondylarthropathy

Symptoms & Phenotypes for Spondylarthropathy

UMLS symptoms related to Spondylarthropathy:


sciatica

Drugs & Therapeutics for Spondylarthropathy

Drugs for Spondylarthropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etanercept Approved, Investigational Phase 4 185243-69-0
2
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
3
Pamidronate Approved Phase 4 40391-99-9 4674
4
Infliximab Approved Phase 4 170277-31-3
5 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
6 Vaccines Phase 4
7 Analgesics, Non-Narcotic Phase 4
8 Analgesics Phase 4
9 Anti-Inflammatory Agents Phase 4
10 Anti-Inflammatory Agents, Non-Steroidal Phase 4
11 Cyclooxygenase 2 Inhibitors Phase 4
12 Cyclooxygenase Inhibitors Phase 4
13 Immunoglobulins Phase 4
14 Antibodies Phase 4
15 Antibodies, Monoclonal Phase 4
16 Gastrointestinal Agents Phase 4
17
Hydroxychloroquine Approved Phase 3 118-42-3 3652
18
Sulfasalazine Approved Phase 3 599-79-1 5359476 5353980
19
Certolizumab pegol Approved Phase 3 428863-50-7
20
tannic acid Approved Phase 3 1401-55-4
21
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
22 Anti-Infective Agents Phase 3
23 Antimalarials Phase 3
24 Antiparasitic Agents Phase 3
25 Antiprotozoal Agents Phase 3
26 Pharmaceutical Solutions Phase 2, Phase 3
27
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
28
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
29
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
30
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
31
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
32
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
33 Neuroprotective Agents Phase 2
34 Methylprednisolone Acetate Phase 2
35 Protective Agents Phase 2
36 Hormone Antagonists Phase 2
37 Hormones Phase 2
38 Antineoplastic Agents, Hormonal Phase 2
39 glucocorticoids Phase 2
40 Antiemetics Phase 2
41
Triamcinolone Approved, Vet_approved Early Phase 1 124-94-7 31307
42
Etoricoxib Approved, Investigational 202409-33-4 123619
43
Adalimumab Approved, Experimental 331731-18-1 16219006
44
Vitamin A Approved, Nutraceutical, Vet_approved 68-26-8, 11103-57-4 445354
45 Triamcinolone diacetate Early Phase 1
46 triamcinolone acetonide Early Phase 1
47 Triamcinolone hexacetonide Early Phase 1
48 retinol
49 Cola
50 Retinol palmitate

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar® Completed NCT00828997 Phase 4
2 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
3 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
4 A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy Completed NCT00420303 Phase 4 Etanercept
5 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding Completed NCT03190603 Phase 4 Celecoxib
6 A Prospective Study of the Use of the Madrid Ultrasound Scoring System in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis Completed NCT02960035 Phase 4 50mg etanercept;25mg etanercept;placebo
7 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
8 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
9 Study of Peripheral Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab Terminated NCT00686894 Phase 4 Infliximab
10 Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Withdrawn NCT00298012 Phase 4 Methotrexate
11 Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS Unknown status NCT02809781 Phase 2, Phase 3 Etanercept
12 A Prospective Double Blind Placebo Controlled Trial of Combination Disease Modifying Antirheumatic Drugs (DMARDs) vs Monotherapy (Sulfasalazine) in Patients With Inflammatory Low Backache in Early Seronegative Spondylarthropathy Completed NCT01040195 Phase 3 Methotrexate, Hydroxychloroquine;Placebo
13 Mechanism of Action Study of Anti-IL17 Treatment in Spondyloarthritis: Impact on Cellular and Molecular Pathways of Synovial Inflammation and Tissue Remodeling Completed NCT03358134 Phase 3 Secukinumab
14 Efficacy, Safety, and Tolerability of Infliximab (Remicade; Schering-Plough) in Juvenile Spondyloarthropathies: a Three-Month, Randomized, Double-Blind, Placebo-Controlled Trial and 52-Week Open Extension. Completed NCT00591201 Phase 2, Phase 3 infliximab;Placebo
15 Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis Completed NCT01087762 Phase 3
16 Intra-articular and Intravenous Infliximab in the Treatment of Resistant Seronegative Oligoarthritis of the Knee Terminated NCT01216631 Phase 2 methylprednisolone;Infliximab;Infliximab
17 Guide-Free Sacroiliac Injection in Spondyloarthropathies Unknown status NCT00829543 Early Phase 1
18 French Cohort on Outcome of Recent Undifferentiated Spondyloarthritis Unknown status NCT01648907
19 Prospective, International, Multi-centre Study on ASAS Classification Criteria for SpA Unknown status NCT00328068
20 Frequency of Axial Spondyloarthropathy Among Patients Suffering From Fibromyalgia - Application of the ASAS Classification Criteria Unknown status NCT01167413
21 Effectiveness and Patient-reported Outcomes in Patients With Spondyloarthropathies Treated With Biological Agents Unknown status NCT02948608
22 Feasibility of an Immersive Virtual Reality Based Biofeedback Intervention for Outpatients in Rheumatology: An Observational Cohort Study Unknown status NCT03459274
23 Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy Unknown status NCT00517101
24 Evaluation of Power Doppler US Technique for the Diagnosis of Spondylarthropathy in Patients With Uncertain Diagnosis Consulting for Clinical Symptoms Suggestive of Spondylarthropathy Completed NCT00794404
25 C.O.R.P.U.S. : Observational Cohort of Active Rheumatoid Arthritis, Spondylarthropathy and Idiopathic Juvenile Arthritis in France Completed NCT02886689 TNF-alpha antagonist and other biotherapy
26 Sarcopenia in Axial and Peripheral Spondyloarthropathies Completed NCT03319264
27 Safety Data on Etoricoxib From Swedish Registries of Spondyloarthropathy/Ankylosing Spondylitis Patients Completed NCT01327638 etoricoxib;Other COX-2 inhibitor;nsNSAIDs
28 Performance of Referral Recommendations in Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis Completed NCT00383617
29 Prevalence of Small Bowel Inflammatory Crohn's Disease Lesions in Patients With Spondyloarthropathies (SpA): A Prospective Capsule Endoscopy-Based Study Completed NCT03064815
30 Long Term Adherence and Efficacy of Etanercept in SpA Iraqi Patients: 7 Year Data From Local Registry Completed NCT04507776 Etanercept
31 Allograft Alone Versus Allograft With Bone Marrow Concentrate for the Healing of the Instrumented Posterolateral Lumbar Fusion Completed NCT01603836
32 Observational Trial on the Value of Diagnostic Criteria in the Diagnosis of Spinal Spondyloarthropathies in Patients With Chronic Low Back Pain Completed NCT00726765
33 Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening Over the 4 Weeks Using a Randomised Control Trial? Completed NCT02436785
34 Non-Interventional Observational Study on Patient Satisfaction With the Benepali® Pre-Filled Pen Completed NCT03327454
35 The Characterization of Small Bowel and Colonic Involvement in Patients With Seronegative Spondyloarthritides Completed NCT00768950
36 Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis Completed NCT02098694
37 Clinical and Dermoscopic Evaluation of Nail Findings of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis Patients and Comparison With Psoriasis Patients Recruiting NCT04709354
38 Effectiveness and Cost-effectiveness of Monitoring Spondyloarthritis With the Integrated eHealth System SpA-Net: a Randomized Controlled Trial Recruiting NCT04673825
39 Faecal Analyses in Spondyloarthritis Therapy: A Prospective Observational Study of the Intestinal Microbiome in Patients With Spondyloarthropathy Receiving TNF-inhibition. Recruiting NCT03839862 TNF-inhibition
40 Cartography and Quantitative Characterization of Achilles Tendon Fibrocartilage by TE = 0ms Imaging at3T MRI Recruiting NCT03287596
41 Employment and Arthritis: Making it Work: A Randomized Controlled Trial Evaluating an On-line Program to Help People With Inflammatory Arthritis Remain Employed Active, not recruiting NCT01852851
42 Impact of Red and Processed Meat and Fibre Intake on Treatment Outcome Among Patients With Chronic Inflammatory Diseases: Protocol for a Prospective Cohort Study on Prognostic Factors and Personalised Medicine Active, not recruiting NCT03173144
43 Intake of Dietary Fibre, Red and Processed Meat and Risk of Late-Onset Chronic Inflammatory Diseases: A Prospective Danish Study on the "Diet, Cancer and Health" Cohort Active, not recruiting NCT03456206
44 Descriptive Study on the Evolution of Intestinal Microbiota Profiles in Patients With Juvenile Spondylarthropathy According to the Typology of Treatment and Response to it: A Descriptive, Prospective Pilot Study Not yet recruiting NCT04540432

Search NIH Clinical Center for Spondylarthropathy

Genetic Tests for Spondylarthropathy

Anatomical Context for Spondylarthropathy

MalaCards organs/tissues related to Spondylarthropathy:

40
Bone, Bone Marrow, T Cells, Spinal Cord, Eye, Endothelial, Small Intestine

Publications for Spondylarthropathy

Articles related to Spondylarthropathy:

(show top 50) (show all 807)
# Title Authors PMID Year
1
Chronic synovitis and HLA B27 in patients with severe haemophilia. 6
12648975 2003
2
Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. 6
8053961 1994
3
Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. 61 54
20022785 2010
4
Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. 54 61
16901960 2006
5
Lack of genetic association of the Toll-like receptor 4 (TLR4) Asp299Gly and Thr399Ile polymorphisms with spondylarthropathies in a Hungarian population. 54 61
16567359 2006
6
Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. 54 61
16603583 2006
7
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. 61 54
16329106 2005
8
[Spondylarthropathies and anti-TNFalpha drugs]. 54 61
16154026 2005
9
Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. 61 54
15986366 2005
10
Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. 61 54
15986373 2005
11
Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options. 61 54
15974637 2005
12
Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. 61 54
15457463 2004
13
Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. 54 61
15146432 2004
14
Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. 54 61
12794836 2003
15
[Anti-cytokines in the treatment of inflammation]. 61 54
12722608 2003
16
[Anti-TNF-alpha treatment--an effective complement in spondyloarthropathy]. 61 54
12572316 2002
17
Efficacy of tumor necrosis factor alpha blockade for enthesitis in spondylarthropathy: comment on the article by Marzo-Ortega et al. 61 54
12483753 2002
18
NADPH oxidase priming and p47phox phosphorylation in neutrophils from synovial fluid of patients with rheumatoid arthritis and spondylarthropathy. 61 54
12546136 2002
19
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. 54 61
11920412 2002
20
Effects of anti-tumor necrosis factor alpha on synovium in patients with spondylarthropathy: comment on the article by Baeten et al. 54 61
11762957 2001
21
Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. 54 61
11592375 2001
22
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. 61 54
11212159 2001
23
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. 54 61
10857793 2000
24
Increased Ed-B fibronectin plasma levels in spondyloarthropathies: comparison with rheumatoid arthritis patients and a healthy population. 61 54
10556262 1999
25
HLA-B27 transgenic rats model. 61 54
11490535 1998
26
Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. 54 61
8843861 1996
27
Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. 61 54
8737721 1996
28
[New aspects in the pathogenesis of Bechterew disease]. 61 54
8868146 1996
29
Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. 54 61
7986220 1994
30
Dialysis-associated spondylarthropathy. Report of 10 cases. 61 54
8151349 1994
31
Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. 54 61
8202660 1994
32
[Leukocyte expression of the LFA-1 adhesion molecule in spondylarthropathies]. 54 61
8000397 1994
33
Complications of axial arthropathies. 54 61
2114600 1990
34
High prevalence of small intestinal bacterial overgrowth (SIBO) in spondylarthropathy. 61
33427609 2021
35
Combined use of different antibody clones improves the efficiency of human leukocyte antigen B27 detection by flow cytometry. 61
33373171 2020
36
Do Smoking and Socioeconomic Factors Influence Imaging Outcomes in Axial Spondyloarthritis? Five-Year Data From the DESIR Cohort. 61
32562362 2020
37
Long-term association between disease activity and disability in early axial spondyloarthritis: results from the DESIR cohort. 61
33207078 2020
38
Diagnostic performance of plain radiography for sacroiliitis in patients with suspected axial spondyloarthritis: a systematic review and meta-analysis. 61
32536262 2020
39
[Assessment of the safety, tolerability and effectiveness of first Russian generic aceclofenac in patients with undifferentiated peripheral inflammatory arthritis]. 61
32598777 2020
40
Clinical manifestations, disease activity and disease burden of radiographic versus non-radiographic axial spondyloarthritis over 5 years of follow-up in the DESIR cohort. 61
31784451 2020
41
Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five-Year Results From the DESIR Cohort. 61
30354022 2019
42
[Biologics in rheumatology]. 61
31485714 2019
43
Evaluation of the predictive validity of the ASAS axial spondyloarthritis criteria in the DESIR cohort. 61
30873948 2019
44
Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study. 61
31335881 2019
45
Low incidence of vertebral fractures in early spondyloarthritis: 5-year prospective data of the DESIR cohort. 61
30389692 2019
46
A patient with spondylarthropathy treated with TNF-α inhibitors presenting with clinical findings suspicious of metastatic cancer disease. 61
30376121 2018
47
A patient with spondylarthropathy treated with TNF-α inhibitors presenting with clinical findings suspicious of metastatic cancer disease. 61
30137507 2018
48
Panorama of inflammatory arthropathies in rheumatologic consultations in Northern Togo. 61
30270840 2018
49
Detection of Crohn Disease in Patients with Spondyloarthropathy: The SpACE Capsule Study. 61
29449505 2018
50
Can power Doppler ultrasound of the entheses help in classifying recent axial spondyloarthritis? Data from the DESIR cohort. 61
30167327 2018

Variations for Spondylarthropathy

ClinVar genetic disease variations for Spondylarthropathy:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HLA-B HLA-B, HLA-B27 Variation risk factor 14908 GRCh37:
GRCh38:

Expression for Spondylarthropathy

Search GEO for disease gene expression data for Spondylarthropathy.

Pathways for Spondylarthropathy

Pathways related to Spondylarthropathy according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 TNF ITGAL HLA-B
2
Show member pathways
12.27 TNF TLR4 ITGAL HLA-B
3
Show member pathways
12.06 TNF ITGAL HLA-B
4 11.88 TNF ITGAL HLA-B
5 11.56 TNF ITGAL CD163
6 11.49 TLR4 ITGAL
7
Show member pathways
11.43 TNF TLR4
8 11.42 TNF TLR4
9 11.39 TNF CD163
10 11.3 TNF TLR4 ITGAL
11 11.25 TNF TLR4
12 11.21 TNF TLR4
13 11.14 TNF TLR4
14 10.98 TNF TLR4
15 10.95 TNF TLR4 ITGAL
16 10.5 TNF TLR4 ITGAL

GO Terms for Spondylarthropathy

Cellular components related to Spondylarthropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.56 TNF TLR4 HLA-B CD163
2 external side of plasma membrane GO:0009897 9.33 TNF TLR4 CD163
3 phagocytic cup GO:0001891 8.96 TNF TLR4
4 cell surface GO:0009986 8.92 TNF TLR4 ITGAL HLA-B

Biological processes related to Spondylarthropathy according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.69 TNF TLR4 HLA-B
2 regulation of inflammatory response GO:0050727 9.58 TNF TLR4
3 positive regulation of interleukin-6 production GO:0032755 9.57 TNF TLR4
4 positive regulation of JNK cascade GO:0046330 9.56 TNF TLR4
5 phagocytosis GO:0006909 9.55 TLR4 ITGAL
6 negative regulation of interleukin-6 production GO:0032715 9.54 TNF TLR4
7 apoptotic signaling pathway GO:0097190 9.52 TNF TLR4
8 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.49 TNF TLR4
9 positive regulation of interferon-gamma production GO:0032729 9.48 TNF TLR4
10 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.46 TNF TLR4
11 positive regulation of interleukin-8 production GO:0032757 9.43 TNF TLR4
12 positive regulation of interleukin-1 beta production GO:0032731 9.4 TNF TLR4
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.37 TNF TLR4
14 positive regulation of chemokine production GO:0032722 9.32 TNF TLR4
15 lipopolysaccharide-mediated signaling pathway GO:0031663 9.26 TNF TLR4
16 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.16 TNF TLR4
17 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 8.96 TNF TLR4
18 inflammatory response GO:0006954 8.92 TNF TLR4 ITGAL CD163

Sources for Spondylarthropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....